Adenoviruses and the immune system join forces against cancer

February 16, 2017, IDIBELL-Bellvitge Biomedical Research Institute
The T cells (in gray) of the immune system surround the tumor cells (in green) thanks to the action of BiTE antibodies secreted by the oncolytic adenovirus. Credit: IDIBELL

Researchers of the Cancer Virotherapy Research Group of Bellvitge Biomedicine Research Institute (IDIBELL), led by Dr. Ramon Alemany, have developed an oncolytic virus capable of redirecting the patient's immune system against tumor cells. Their work, published in Cancer Research, may lead to the development of new therapeutic strategies for several types of cancer.

"We work with oncolytic adenoviruses, which are viruses modified to attack cancer cells exclusively, without attacking normal tissue, as a targeted therapy," explains Carlos Fajardo, lead author of the study. Adenoviruses are a family of viruses that can cause colds, conjunctivitis or gastroenteritis. However, these viruses, once modified to acquire selectivity towards , have great potential to be used as cancer therapy.

There are several limitations in this field; one of them is that the recognizes such viruses as pathogens and therefore attacks them. "What we are trying to do is redirect the immune system to attack the cancer cells instead of the virus. In this way, we not only prevent the virus from being eliminated from the organism too soon, but complement its action by adding that of T ," says Fajardo.

To achieve this, the researchers used the newly developed BiTE antibodies (bispecific T-cell engager antibodies). These antibodies are capable of specifically connecting T lymphocytes with some proteins expressed on the surface of cancer cells; this connection activates the T cell, which then attacks and destroys the cell.

"We modified the virus so that when it infects the tumor cell, it secretes a specific BiTE against the EGFR protein, which is overexpressed in many types of cancer." In vitro studies revealed that these BiTEs were able to capture the T lymphocytes present in the medium to attack adjacent . In addition, mouse studies demonstrated that the virus armed with BiTE were able to increase the presence of T lymphocytes in tumors, resulting in improved antitumor efficacy.

In recent years, virotherapy for cancer treatment has become an active research field, thanks to advances in immunotherapy. "With these results, we will try to attract the interest of the companies that develop BiTEs to establish collaboration agreements for the clinical development of viruses armed with BiTEs," said Dr. Alemany, the last author of the study. "We are also exploring the development of that target T lymphocytes against tumor stroma fibroblasts to eliminate them".

Explore further: Silencing cancer cell communication may reduce the growth of tumors

More information: Carlos A Fajardo et al, Oncolytic adenoviral delivery of an EGFR-targeting T cell engager improves antitumor efficacy, Cancer Research (2017). DOI: 10.1158/0008-5472.CAN-16-1708

Related Stories

Silencing cancer cell communication may reduce the growth of tumors

January 30, 2017
In several types of cancer, elevated expression of the chemokine receptor CCR4 in tumors is associated with poor patient outcomes. Communication through CCR4 may be one mechanism that cancer cells use to create a pro-tumor ...

T cell channel could be targeted to treat head and neck cancers

November 17, 2016
Researchers at the University of Cincinnati (UC) have discovered that an ion channel, active within T cells (white blood cells), could be targeted to reduce the growth of head and neck cancers.

Junction opening protein boosts cancer-killing effect of oncolytic virus

May 10, 2016
A new study shows that the anti-tumor effect of oncolytic virus therapy is significantly greater in mice when the virus is genetically modified to express a junction opening (JO) protein, which helps the cancer-killing agent ...

New subtypes of lung cancer can lead to personalized therapies with better outcome

October 24, 2016
Personalized therapies can potentially improve the outcomes of patients with lung cancer, but how to best design such an approach is not always clear. A team of scientists from Baylor College of Medicine and the University ...

Antibody appears to attack cancer cells, leaving other cells unscathed

May 5, 2016
A research team from Duke Health has developed an antibody from the body's own immune system that preferentially attacks cancer cells.

Viruses kill pancreatic tumors in preclinical model

March 20, 2012
(Medical Xpress) -- An intra-tumor injection of a virus prevented further growth of some pancreatic tumors and eradicated others in mouse models of pancreatic ductal adenocarcinoma. However, some tumors continued growing ...

Recommended for you

RNA thought to spread cancer shows ability to suppress breast cancer metastasis

October 22, 2018
Researchers at The University of Texas MD Anderson Cancer Center have discovered that a form of RNA called metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) appears to suppress breast cancer metastasis in mice, ...

Revealing the molecular mystery of human liver cells

October 22, 2018
A map of the cells in the human liver has been created by University Health Network Transplant Program and University of Toronto researchers, revealing for the first time differences between individual cells at the molecular ...

Targeting a hunger hormone to treat obesity

October 22, 2018
About 64 per cent of Canadian adults are overweight or obese, according to Health Canada. That's a problem, because obesity promotes the emergence of chronic diseases such as type 2 diabetes, heart disease and some cancers.

New tool gives deeper understanding of glioblastoma

October 22, 2018
Researchers in the lab of Charles Danko at the Baker Institute for Animal Health have developed a new tool to study genetic "switches" active in glioblastoma tumors that drive growth of the cancer. In a new paper in Nature ...

Pancreatic cancer genetic marker may predict outcomes with radiation therapy

October 22, 2018
Pancreatic cancer is one of the most difficult cancers to treat and is a leading cause of cancer-related deaths. Now, Sidney Kimmel Cancer Center—Jefferson Health and Lankenau Institute for Medical Research scientists find ...

New drug combination destroys chemo-resistant blood cancer

October 22, 2018
Researchers from The Ottawa Hospital and the University of Ottawa have developed a promising targeted strategy to treat chemotherapy-resistant acute myeloid leukemia (AML) and a diagnostic test to determine which AML patients ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.